Orforglipron (brand name Foundayo) — Metabolic & Weight Loss

Published · Researched 2026-09-21

Item chosen: ORFORGLIPRON (slug: orforglipron) — Eli Lilly, FDA-approved brand Foundayo. Swap note: Setmelanotide (Candidate A) failed the community-discussion bar — Threads returned only 2 posts (an EASO journal-article share, Dec 2024; a link-drop, Jul 2023), neither owner/user discussion in a weight-loss context, and Facebook found zero groups matching "setmelanotide". Orforglipron cleared it: multiple identifiable Threads discussion threads (including a physician) plus relevant active GLP-1/peptide Facebook Groups. Also note: orforglipron is a small-molecule non-peptide GLP-1 receptor agonist, NOT a peptide — relevant for a peptide-research project; kept because it is what the weight-loss community is actually talking about. Research date: September 20, 2026. All prices dated below.

1. Overview

  • Maker: Eli Lilly and Company.
  • Molecule: Orforglipron (development code LY3502970) — a once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist.
  • Brand / approval status (as of Sept 2026): FDA approved April 1, 2026 as Foundayo™ (orforglipron) for adults with obesity or overweight with weight-related medical problems. It was the fifth drug approved under the FDA's Commissioner's National Priority Voucher (CNPV) program — approved 50 days after filing, 294 days ahead of its January 20, 2027 PDUFA date (BioSpace, Mar 23, 2026; MarketBeat FDA-events log).
  • Launch: Prescriptions accepted via LillyDirect immediately; shipping began April 6, 2026; retail pharmacies and telehealth followed. Lilly had stockpiled ~$1.5 billion worth of product ahead of launch (BioSpace, Mar 23, 2026).
  • Why it matters: First oral GLP-1 weight-loss pill that can be taken at any time of day with no food or water restrictions — unlike oral semaglutide (Rybelsus/Wegovy pill), which requires empty-stomach dosing with ≤4 oz water and a 30-minute wait. Novo Nordisk's Wegovy pill (approved late 2025, launched Jan 5, 2026) hit ~20,000 prescriptions in its first two U.S. weeks; Foundayo is the direct rival (Fierce Pharma, ~Apr 2026).
  • ATTAIN program status (Sept 2026): The two global registration trials (enrolled >4,500 people) are complete:
    • ATTAIN-1 (obesity/overweight, no diabetes; n=3,127) — topline Aug 7, 2025 (Lilly press release); full results published in The New England Journal of Medicine and presented at EASD, Sept 2025 (PMID 40960239).
    • ATTAIN-2 (obesity/overweight with type 2 diabetes; n=1,613) — positive topline announced Aug 26, 2025; all three doses met primary and key secondary endpoints.
  • Under study (not approved) as of Sept 2026: type 2 diabetes (ACHIEVE program, incl. ACHIEVE-1 and ACHIEVE-3 vs oral semaglutide), obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease, stress urinary incontinence (HCPLive, Apr 1, 2026).

2. Social standing

Platform pulse:

  • Threads — strong. The dominant discussion layer for this molecule. Recurring themes: the 12.4% Phase 3 figure, the no-food/water-restriction dosing convenience, bioavailability debates, and — post-approval — ad fatigue around the Foundayo brand.
  • Facebook Groups — weak-but-present. Relevant groups exist and are active: "Zepbound support and success" (~1,000 members), "Zepbound Meals And Motivation" (~1,000), "Peptides For Weight loss And Fitness Wellness" (597), "Peptides for Beginners" (4,000), "GLP-1 Care & Conversation" (485), "Weight Loss Support on GLP-1 Medications" (427). Group-post bodies are redacted through the CLI, so per-post orforglipron discussion inside these groups could not be verified — group-level presence only.
  • Instagram — not assessed. No public search available via the connected account; cross-platform social search was down on the research date.

Group consensus (from what is visible): Excitement centers on convenience (a daily pill with no food rules), not superiority — no one claims it beats injectable tirzepatide on raw weight loss. The physician-level conversation is about whether oral bioavailability is "good enough" relative to injections. Complaints are dominated by advertising saturation, not efficacy or safety.

Verified quotes (attributed by platform + context):

  1. Threads — @lin_offline (physician, 林明頡 醫師), Sep 14, 2026: "上週參加禮來的研討會，說orforglipron 生物使用率有77%，已經不輸針劑了（官方數據）" — i.e., at a Lilly seminar, claimed orforglipron bioavailability is 77% and "not inferior to injections (official data)". ⚠️ Conflicts with published pharmacokinetic data (30–40% oral bioavailability); log as UNVERIFIED/UNCONFIRMED.
  2. Threads — @ling_yang0825, Sep 14, 2026 (2 replies): "口服的吸收率沒有針劑好吧" ("oral absorption can't be as good as injections") — the skeptical counterpoint in the same thread cluster.
  3. Threads — widely reshared explainer thread, Aug 7, 2025 (126 likes, 10 replies, 5 reposts; posting handle not captured in search excerpt): "Eli Lilly's Groundbreaking GLP-1 Pill — What You Need to Know 🧵 🆕 Big news today: Eli Lilly's experimental oral GLP-1 pill, orforglipron, delivered an average weight loss of 12.4% in a late-stage (Phase 3) trial over 72 weeks, versus less than 1% in the placebo group. … Unlike current injectable GLP-1 drugs (like Ozempic or Wegovy), this is a daily oral pill — no needles, no refrigeration. Could be a game-changer for accessibility." (No-refrigeration claim UNVERIFIED against the label.)
  4. Threads — @quesoquantum, Sep 20, 2026 (4 likes): "STOP SHOWING ME MOUNJARO AND FOUNDAYO I DONT CAREEEE" — post-launch ad-fatigue complaint.
  5. Threads — @booksnaxx, Sep 19, 2026 (7,087 likes, 77 replies): "Every streaming platform should allow their customers to turn off ads for sports betting and weight loss drugs." — ambient weight-loss-drug ad fatigue; not Foundayo-specific but reflects the ad-saturation environment Foundayo launched into.
  6. Threads — @docjuanubaldo (Spanish, Sep 20, 2026): "Recientemente se aprobó Orforglipron, un nuevo aGLP-1 oral. Foundayz (México) o Foundayo, de Eli Lilly. Tiene la ventaja además de poder consumirse a cualquier hora del día, con o sin alimentos. Está aprobado para Diabetes y Obesidad." — highlights the any-time dosing; the "approved for diabetes" and "Foundayz (Mexico)" claims are UNVERIFIED.

3. Social validation — Tier 2

Tier: Tier 2 — Threads + Facebook Groups both present; Instagram unassessed. Flag: Facebook contribution is weak (group presence only; no verifiable post-level discussion).

Named sources — what each proves:

Source Platform What it proves
@lin_offline (physician) + @ling_yang0825 reply cluster, Sep 14, 2026 Threads Identifiable owner/professional + user discussion of orforglipron bioavailability in a weight-loss context
Explainer thread, Aug 7, 2025 (126 likes, 10 replies, 5 reposts) Threads Viral ATTAIN-1 readout moment; community reach of the 12.4% figure
@quesoquantum + @booksnaxx, Sep 19–20, 2026 Threads Post-launch brand awareness high enough to generate ad-fatigue complaints
@docjuanubaldo, Sep 20, 2026 Threads International awareness (Latin America); brand-name recognition
"Zepbound support and success" (~1,000 members), "Zepbound Meals And Motivation" (~1,000), "Peptides for Beginners" (4,000), "Peptides For Weight loss And Fitness Wellness" (597), "GLP-1 Care & Conversation" (485), "Weight Loss Support on GLP-1 Medications" (427) Facebook Groups Relevant community presence exists; per-post orforglipron content not verifiable via CLI (bodies redacted)

No sponsored content was identified in the social samples reviewed.

4. Key specs

Spec Detail
Mechanism Selective, high-affinity partial agonist of the GLP-1 receptor; G-protein-biased over β-arrestin recruitment (no meaningful β-arrestin/receptor internalization). Non-peptide small molecule — enables oral delivery without an absorption enhancer.
Administration route Oral tablet, once daily, any time of day, with no food or water restrictions (prandial state has no clinically meaningful PK effect)
Half-life ~25–68 hours (supports once-daily dosing); Tmax 2–4 h; oral bioavailability ~30–40% (PMC review, PMID-indexed). ⚠️ A Threads physician claimed 77% bioavailability from a Lilly seminar — conflicts with published data; UNCONFIRMED.
Dosing schedule Foundayo label: start 0.8 mg once daily; step-wise 4-week titration → maintenance 5.5 mg, 9 mg, or 17.2 mg daily (via steps 0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg). ATTAIN-1/2 trial doses were 6 mg, 12 mg, and 36 mg.
Trial data — ATTAIN-1 Phase 3, 72 weeks, n=3,127, obesity/overweight without diabetes. Topline announced Aug 7, 2025 (Lilly); full data NEJM + EASD Sept 2025. Mean weight change (efficacy estimand): −7.8% (6 mg), −9.3% (12 mg), −12.4% (36 mg) vs −0.9% placebo (≈27.3 lbs at top dose). Treatment-regimen estimand: −7.5%/−8.4%/−11.2% vs −2.1%. ≥10% loss: 59.6% at 36 mg (vs 8.6% placebo); ≥15%: 39.6%; ≥20%: 20.1%. Up to 91% of prediabetes participants reached near-normal glycemia vs 42% placebo. hsCRP −47.7% at top dose (exploratory).
Trial data — ATTAIN-2 Phase 3, 72 weeks, n=1,613, obesity/overweight with type 2 diabetes. Positive topline Aug 26, 2025 (all doses met primary + key secondaries): 36 mg → −9.6% vs −2.5% placebo at 72 weeks, plus significant A1C and cardiometabolic improvements.
Safety signals GI-dominant, mostly mild–moderate, worst during titration: nausea, constipation, diarrhea, vomiting, dyspepsia. AE-discontinuation: 5.1% (6 mg), 7.7% (12 mg), 10.3% (36 mg) vs 2.6% placebo. No hepatic safety signal (Chugai/Lilly release, Aug 2025). Boxed warning: thyroid C-cell tumors. Other labeled risks: pancreatitis, gallbladder disease, dehydration→kidney injury, severe GI disease, vision changes in T2D, aspiration risk during surgery.
Comparison context Less weight loss than injectable tirzepatide (~20%+ in SURMOUNT), more than placebo; convenience (pill, no food rules) is the selling point vs injections. Direct rival: Novo's oral Wegovy pill (approved late 2025, launched Jan 5, 2026).

5. Pricing (DATED — all figures observed/reported Sept 2026 unless noted)

  • Brand list price (MSRP/WAC): $649.00/month for all Foundayo strengths (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg; 30-tablet packs, NDC 0002-4178-31 through 0002-4953-31), per Lilly's official WAC disclosure sheets (CT/CO), AnalySource data accessed 04/02/2026.
  • LillyDirect self-pay: $25/month with commercial coverage + savings card; $149/month self-pay (0.8 mg starting dose); $199/month (2.5 mg); $299/month (5.5–17.2 mg); loyalty refills within 45 days: $299/month on the 14.5/17.2 mg doses (UBS/Jefferies, reported Apr 2026). UBS reported highest-dose cash price of $349/month; TrumpRx government price $346/month; Medicare Part D GLP-1 Bridge $50/month starting July 1, 2026 (Lilly release, Apr 1, 2026).
  • Gray-market / research-chemical prices (NOT pharmaceutical grade, not for human use):
    • Alpha Omega Peptide — Orforglipron 6 mg, 90 capsules: $239 in stock (bulk: 5% off at 5–9 units, 12% off at 10+ ≈ $210.32). Price displayed in live search Sept 20, 2026; page last crawled ~Dec 2025.
    • Real Peptides — Orforglipron capsules: $220 (page updated ~mid-Aug 2026).
    • TargetMol (lab reagent, CAS 2212020-52-3): $52 (1 mg), $123 (5 mg), solutions $39.
  • Marketplace used range: none observed — UNVERIFIED/not found.
  • ⚠️ Pricing discrepancy note: investors.com (Apr 2026) reported a "full list price" of $349/month; Lilly's official WAC is $649/month. The $349 figure aligns with the reported highest-dose cash-pay price, not list. Both are reported with sources; treat $649 as the official list price.

6. What is included / what else is needed

  • Brand Foundayo: 30-count bottle of once-daily tablets at the prescribed strength; titration blister scheduling via prescriber. Taken with reduced-calorie diet + increased physical activity per label. No needles, no reconstitution; room-temperature storage (not a cold-chain product like injectable GLP-1s).
  • Gray-market capsules: capsules only; no medical guidance, no prescription, no quality/purity testing — sold under "research use only" disclaimers. Purity/identity claims (e.g., "99.89%") are vendor self-reported and UNVERIFIED.
  • What else is needed (brand): prescription; prior authorization with many commercial plans; BMI ≥30 (or ≥27 with weight-related comorbidity); monthly refills; ongoing lifestyle program.
  • Do NOT use with: other GLP-1 receptor agonists. Not established in children.

7. Support reality

  • Brand (Lilly): standard pharmaceutical support — LillyDirect (free home delivery, telehealth partners), manufacturer savings card, prior-authorization support. No "warranty/returns" concept applies; no community-reported support-failure incidents found.
  • Gray-market vendors: sell under "research use only" disclaimers with no medical support. No verified community reports of support quality for orforglipron gray-market sellers were found — support reputation UNVERIFIED.
  • Community-reported friction: not about support — the dominant complaint in social samples is ad saturation (Threads, Sep 2026).

8. Community verdict

Orforglipron/Foundayo is the weight-loss community's most-discussed oral GLP-1 precisely because it removes the friction that kept people off injectables — a daily pill with no food or water rules and published Phase 3 data showing ~12% average weight loss. The open question the community keeps circling is whether oral bioavailability is "good enough" versus shots, and the newest sentiment is simply fatigue at how heavily the brand is being advertised. No one in the sampled discussions disputes the trial numbers; expectations are anchored on convenience, not on beating tirzepatide.

9. Regulatory & safety status

  • Regulatory (as of Sept 2026): FDA-APPROVED — Foundayo (orforglipron) approved April 1, 2026 for adults with obesity or overweight with weight-related medical problems (fast-tracked under the CNPV program). NOT approved for type 2 diabetes in the US (ACHIEVE program ongoing; ACHIEVE-1/ACHIEVE-3 readouts exist but no T2D indication as of this writing — a Threads poster claimed diabetes approval; UNVERIFIED for US).
  • EU/EMA: not covered by the sources found — status UNVERIFIED.
  • Gray-market capsules/powder: sold as "research chemicals, not for human use"; unregulated — no FDA oversight of identity, purity, or sterility. The FDA's April 2026 safety communication explicitly warned about compounded/unapproved GLP-1 products.
  • Plain-language safety: In trials, the common side effects were stomach-related (nausea, vomiting, diarrhea, constipation), mostly mild–moderate and worst while doses were being raised; ~5–10% of trial participants stopped because of side effects. The label carries a boxed warning for thyroid C-cell tumors (do not use with personal/family history of medullary thyroid carcinoma or MEN 2) plus warnings for pancreatitis, gallbladder problems, kidney injury from dehydration, and severe stomach/intestinal disorders.

10. Missing-image views + UNVERIFIED points log

UNVERIFIED points:

  1. 77% bioavailability claim (Threads physician, Sep 2026) — contradicts published 30–40%.
  2. "Approved for diabetes" claim (Threads, Spanish, Sep 2026) — US label is obesity/overweight only; possible Mexico-specific status not confirmed.
  3. "Foundayz (México)" brand spelling — unconfirmed.
  4. "No refrigeration needed" (Threads explainer) — not confirmed against the label; plausible for a small-molecule tablet.
  5. Instagram owner content — not assessed (no public search access).
  6. Facebook group per-post orforglipron discussion — bodies redacted via CLI.
  7. Explainer thread (Aug 7, 2025) posting handle — not captured.
  8. investors.com "$349 full list price" vs Lilly WAC $649 — reported both; treat $649 as official.
  9. Gray-market price observation dates — pages show prices live Sept 20, 2026, but vendor page freshness varies.
  10. EMA/EU approval status — not found.
  11. Marketplace used/resale range — none found.

Images (7 real photos saved, all verified photographic, none AI-generated; swisschems.pk candidate failed HEAD check and was rejected):

  • img/orforglipron-hero.jpg — hero: official Lilly press lineup of all six Foundayo bottle strengths (0.8→17.2 mg) with tablets
  • img/orforglipron-side.jpg — side/alternate angle: Foundayo 0.8 mg bottle angled with three tablets (white/purple/red "Lilly"-embossed)
  • img/orforglipron-top.jpg — alternate angle: split image of fingers holding a peach "L" tablet + Foundayo 0.8 mg bottle (telehealth press asset)
  • img/orforglipron-detail.jpg — detail: close-up of two Foundayo tablets (purple oval "Lilly", peach round "L" embossing)
  • img/orforglipron-owner-in-use.jpg — owner-in-use: hand holding a vendor-labeled orforglipron 3 mg/30-tablet bottle
  • img/orforglipron-scale.jpg — scale: Foundayo-type tablet in palm with 1/4-inch measurement inset
  • img/orforglipron-box-accessories.jpg — box/accessories: gray-market SwissChems orforglipron 90-capsule (6 mg) research bottle with capsules visible
  • Missing view: rear — no usable rear-angle photo found; not fabricated.

Not medical advice. This is research material only; consult a qualified clinician.

Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — box-accessories view
box-accessories view Original vendor page URL not recorded in research dossier
Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — detail view
detail view Original vendor page URL not recorded in research dossier
Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — hero view
hero view Original vendor page URL not recorded in research dossier
Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — owner-in-use view
owner-in-use view Original vendor page URL not recorded in research dossier
Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — scale view
scale view Original vendor page URL not recorded in research dossier
Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — side view
side view Original vendor page URL not recorded in research dossier
Orforglipron (brand name Foundayo) — Metabolic & Weight Loss — top view
top view Original vendor page URL not recorded in research dossier

Named sources

  • Threads @lin_offline — Threads — @lin_offline (physician, 林明頡 醫師), Sep 14, 2026: *"上週參加禮來的研討會，說orforglipron 生物使用率有77%，已經不輸針劑了（官方數據）"* — i.e., at a Lilly seminar, claimed orforglipron bioavailability is 77% and "not inferior to injections (official data)". (Sep 14, 2026)
  • Threads @ling_yang0825 — Threads — @ling_yang0825, Sep 14, 2026 (2 replies): *"口服的吸收率沒有針劑好吧"* ("oral absorption can't be as good as injections") — the skeptical counterpoint in the same thread cluster. (Sep 14, 2026)
  • Threads @quesoquantum — Threads — @quesoquantum, Sep 20, 2026 (4 likes): *"STOP SHOWING ME MOUNJARO AND FOUNDAYO I DONT CAREEEE"* — post-launch ad-fatigue complaint. (Sep 20, 2026)
  • Threads @booksnaxx — Threads — @booksnaxx, Sep 19, 2026 (7,087 likes, 77 replies): *"Every streaming platform should allow their customers to turn off ads for sports betting and weight loss drugs."* — ambient weight-loss-drug ad fatigue; not Foundayo-specific but reflects the… (Sep 19, 2026)
  • Threads @docjuanubaldo — Threads — @docjuanubaldo (Spanish, Sep 20, 2026): *"Recientemente se aprobó Orforglipron, un nuevo aGLP-1 oral. (Sep 20, 2026)
  • PMC review — **Half-life** | ~25–68 hours (supports once-daily dosing); Tmax 2–4 h; oral bioavailability ~30–40% (PMC review, PMID-indexed).
  • Lilly — - **Brand list price (MSRP/WAC):** **$649.00/month** for all Foundayo strengths (0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg; 30-tablet packs, NDC 0002-4178-31 through… (2026)
  • CLI — 6.

Source URLs were not recorded for these references.